Metabolic disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:08:46 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Metabolic disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of GLM101 for Patients with PMM2-CDG https://clinicaltrials.eu/trial/study-on-the-effects-of-glm101-for-patients-with-pmm2-cdg/ Wed, 29 Apr 2026 14:30:01 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-glm101-for-patients-with-pmm2-cdg/ This clinical trial is focused on studying a rare genetic disorder called Phosphomannomutase 2 deficiency (PMM2-CDG). PMM2-CDG is a condition that affects various parts of the body and can lead to problems with movement, balance, and coordination, known as ataxia. The trial will investigate a treatment called GLM101, which is administered through an injection or infusion directly into the bloodstream. The active ingredient in GLM101 is a chemical compound known as alfa-d-mannopyranosyl phosphate dipotassium.

The purpose of this study is to understand how GLM101 affects the symptoms of PMM2-CDG, particularly focusing on changes in ataxia over a period of 12 and 24 weeks. Participants in the study will receive multiple doses of GLM101, and the trial will monitor how the body processes the medication, as well as its safety and tolerability. Some participants may receive a placebo instead of GLM101 to help compare the effects of the treatment.

The study will last for 24 weeks, during which participants will undergo regular assessments to track their progress and any changes in their condition. These assessments will include various tests and observations to ensure the safety of the participants and to gather information on how the treatment is working. The trial aims to provide valuable insights into the potential benefits of GLM101 for individuals with PMM2-CDG.

]]> Long-Term Safety Study of GLM101 for Patients with PMM2-CDG https://clinicaltrials.eu/trial/long-term-safety-study-of-glm101-for-patients-with-pmm2-cdg/ Wed, 29 Apr 2026 14:28:07 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-glm101-for-patients-with-pmm2-cdg/ This clinical trial is focused on studying a rare genetic disorder called PMM2-CDG, which stands for Phosphomannomutase 2 Congenital Disorder of Glycosylation. This condition affects the body’s ability to properly process certain sugars, leading to a variety of health issues. The study involves a treatment called GLM101, which is administered through an injection or infusion directly into the bloodstream. GLM101 contains a substance known as alfa-d-mannopyranosyl phosphate dipotassium, which is designed to help manage the symptoms of PMM2-CDG.

The purpose of this study is to examine the safety of GLM101 in patients who have previously received this treatment. Participants will receive GLM101 over a period of time, and their health will be monitored to gather information on any side effects or changes in their condition. The study will also look at how the treatment affects certain symptoms of PMM2-CDG, such as coordination and balance issues, which are measured using a tool called the International Co-operative Ataxia Rating Scale (ICARS). Additionally, the study will measure the levels of a sugar called Mannose-1-Phosphate in the blood, which is a component of GLM101.

Throughout the study, participants will undergo regular health checks, including blood and urine tests, heart monitoring with an ECG (a test that records the electrical activity of the heart), and assessments of vital signs like blood pressure and body temperature. These evaluations will help researchers understand the effects of GLM101 and ensure the safety of the participants. The study is expected to continue for several years, allowing for a comprehensive assessment of the treatment’s long-term impact on individuals with PMM2-CDG.

]]> Study on Semaglutide for Weight Control in Patients with Schizophrenia and High BMI Using Antipsychotics https://clinicaltrials.eu/trial/study-on-semaglutide-for-weight-control-in-patients-with-schizophrenia-and-high-bmi-using-antipsychotics/ Wed, 29 Apr 2026 14:22:58 +0000 https://clinicaltrials.eu/trial/study-on-semaglutide-for-weight-control-in-patients-with-schizophrenia-and-high-bmi-using-antipsychotics/ This clinical trial is focused on patients who are using antipsychotic medications and are experiencing issues with their metabolic control. The study is investigating the effects of a treatment called semaglutide, which is administered as a solution for injection. Semaglutide is also known by the code name NNC0113-0217 and is being compared to a placebo. The purpose of the study is to explore how semaglutide can help manage body weight in patients with certain conditions.

Participants in this study will include individuals with schizophrenia spectrum disorders who have a Body Mass Index (BMI) of 30 or higher, or a BMI of 27 or higher if they also have prediabetes. Prediabetes is identified by specific levels of blood sugar and a measure called HbA1c. The study will last for 26 weeks, during which participants will receive either semaglutide or a placebo once a week. The main focus is to observe changes in body weight from the start to the end of the study.

Throughout the study, various health indicators will be monitored, including blood sugar levels, cholesterol, and other factors related to heart health. Additionally, the study will assess changes in cognitive function, quality of life, and other health outcomes. The goal is to understand the potential benefits of semaglutide for improving metabolic health in patients taking antipsychotic medications.

]]>